Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 13, 2015 09:31 ET | Source: Amarantus BioScience Holdings, Inc.

Amarantus to Present at Noble Financial Capital Markets' Eleventh Annual Investor Conference

SAN FRANCISCO and GENEVA, Jan. 13, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostics in neurology and...
January 12, 2015 08:35 ET | Source: Amarantus BioScience Holdings, Inc.

Amarantus Announces Acquisition of Specialized Neuro-Diagnostics Company, DioGenix

Lead Product MSPrecise®: Clinically Validated, First-In-Class Next-Generation Sequencing (NGS) Assay that Identifies Multiple Sclerosis (MS) at First Clinical Presentation Recent...
January 08, 2015 07:00 ET | Source: Amarantus BioScience Holdings, Inc.

Amarantus to Participate in the Eighth Annual OneMedForum Conference on January 12 - 13, 2015

SAN FRANCISCO and GENEVA, Jan. 8, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostics in Alzheimer's disease...
December 29, 2014 07:00 ET | Source: Amarantus BioScience Holdings, Inc.

Amarantus to Present LP-002 Data for Alzheimer's Blood Diagnostic LymPro Test(R) at Biotech Showcase 2015 Conference on January 14, 2015

SAN FRANCISCO and GENEVA, Dec. 29, 2014 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostics in Alzheimer's disease...
December 23, 2014 16:00 ET | Source: Amarantus BioScience Holdings, Inc.

Amarantus Receives Orphan Drug Designation for MANF From U.S. Food and Drug Administration for Treatment of Retinitis Pigmentosa

SAN FRANCISCO and GENEVA, Dec. 23, 2014 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostics in Alzheimer's disease...
December 22, 2014 07:00 ET | Source: Amarantus BioScience Holdings, Inc.

Amarantus Commences Launch of Proprietary Alzheimer's Blood Diagnostic LymPro Test(R) to Pharmaceutical Industry for Use in Clinical Trials

SAN FRANCISCO and GENEVA, Dec. 22, 2014 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostics in Alzheimer's disease...
December 19, 2014 07:35 ET | Source: Amarantus BioScience Holdings, Inc.

Amarantus Submits Orphan Drug Designation Application to US FDA for Treatment of Retinal Artery Occlusion With Product Candidate MANF

SAN FRANCISCO and GENEVA, Dec. 19, 2014 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostics in Alzheimer's disease...
December 19, 2014 07:00 ET | Source: Amarantus BioScience Holdings, Inc.

Amarantus Announces Second Closing of Series E Preferred Financing

SAN FRANCISCO and GENEVA, Dec. 19, 2014 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostics in Alzheimer's disease...
December 11, 2014 08:00 ET | Source: Amarantus BioScience Holdings, Inc.

Amarantus Appoints Elise Brownell, Ph.D., as Senior Vice President of Operations and Project Management

SAN FRANCISCO and GENEVA, Dec. 11, 2014 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostics and therapeutic products...
December 08, 2014 08:00 ET | Source: Amarantus BioScience Holdings, Inc.

Amarantus Appoints Renowned Drug Development Expert and Co-Founder of Amgen, Joseph Rubinfeld, Ph.D., to Its Board of Directors

SAN FRANCISCO and GENEVA, Dec. 8, 2014 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostics and therapeutic products...